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Abstract
OBJECTIVE—To evaluate an employer-based diabetes/prediabetes screening intervention that 
invited at-risk employees via letters, secure emails, and automated voice messages to complete 
blood glucose testing at a health plan facility.
METHODS—Quasi-experimental cohort study among health plan members insured by two 
employers that received the intervention and three employers that were selected as control sites.
RESULTS—The proportion of at-risk members that completed a screening was higher in the 
intervention group than in the control group (36% vs. 13%, P < .001, adjusted for patient 
characteristics). Among those screened in the intervention group, the presence of obesity, 
hypertension, hyperlipidemia, and tobacco use were significant predictors of having a result which 
indicated diabetes or prediabetes (P < .05, all comparisons).
CONCLUSIONS—A low-intensity, employer-based intervention conducted in collaboration with 
a health care delivery system effectively increased screening for diabetes/prediabetes.
Over 8 million people in the United States have undiagnosed diabetes.1 In 2010 over 70 
million people were unaware that they had prediabetes, a condition characterized by 
elevated blood glucose levels and an increased risk of developing type 2 diabetes.2 In order 
to reduce those numbers, the American Diabetes Association (ADA) and U.S. Preventive 
Services Task Force (USPSTF) recommend screening asymptomatic adults age 45 years or 
older and younger adults with risk factors such as being overweight, having hypertension, or 
having a first-degree relative with diabetes.3, 4 Early detection of diabetes is advantageous 
because ongoing treatment and support can reduce the risk of long-term complications.3 For 
patients with prediabetes, there is mounting evidence that intensive lifestyle interventions 
can delay or even prevent the onset of type 2 diabetes.5-8
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While more extensive screening will improve the recognition of diabetes and prediabetes, 
the issue of follow-up care provides challenges. Identifying diabetes and prediabetes 
requires a blood glucose test that can be administered by screening programs even outside of 
the primary care setting. Community-based screening programs have occurred in churches, 
community centers, dental offices, and pharmacies.9-11 Similarly, many employee wellness 
programs provide biometric health screening, including blood glucose testing for diabetes, at 
the worksite.12, 13 However, these community- and workplace-based screenings may be 
poorly targeted (i.e. testing those at low risk) and may not provide the appropriate follow-up 
care to patients with a positive screen.3, 9-11 Furthermore, as sharing the screening results 
with primary care physicians is desirable but logistically challenging,14 employer-based 
screening may not activate the health system to provide treatment to patients found to have 
diabetes or prediabetes. Due to these issues with appropriate testing and follow-up, the ADA 
maintains that screening should be performed within a health care setting.3
The purpose of this paper is to evaluate an employer-based intervention to increase 
screening for diabetes and prediabetes by inviting at-risk employees to voluntarily report to 
their health care provider for a blood glucose test. This novel approach, conducted as 
partnership between two employers and an integrated health care delivery system, allowed 
for the screening to take place within the health care setting and for the employees’ primary 
care physicians to have access to the results. This low-intensity screening intervention did 
not provide follow-up care directly, but instead relied on the usual care of the health system 
to respond to newly identified cases of diabetes and prediabetes.
Research Design and Methods
Study design
In 2012, Kaiser Permanente Northern California (KPNC) and two employers implemented a 
diabetes/prediabetes screening program that provided direct outreach to employees who 
were at-risk for diabetes or prediabetes. To evaluate the screening program, we conducted a 
quasi-experimental cohort study15 that compared the two participating employer sites (i.e., 
the intervention group) with employer sites that were not part of the intervention (i.e., the 
control group) on the proportion of at-risk employees who were screened within six months 
and the proportion of the screened who had elevated blood glucose levels. We selected three 
non-participating employers as control sites based on their similarity to the intervention sites 
with regard to industry (public university and county agency) and employee characteristics 
(mean age, gender, and diabetes prevalence). Both groups received the usual care provided 
by the health plan, both in terms of blood glucose testing and follow-up care for patients 
with diabetes or prediabetes. These analyses were conducted as part of the Natural 
Experiments for Translation in Diabetes (NEXT-D) Study and approved by the KPNC 
Institutional Review Board.
Study setting and population
This study was conducted among the current or retired employees of two state universities 
and three county-level government agencies in Northern California who obtained employer-
provided health coverage through KPNC. KPNC is a nonprofit integrated health care 
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delivery system of 48 medical facilities that provides comprehensive medical care to over 
3.5 million members. KPNC members are broadly representative of the local and statewide 
population.16
Eligibility/ineligibility
Employees were found to be at-risk for diabetes/prediabetes and included in the study if they 
met at least one of the following criteria: (a) aged 45 or older and had not had a fasting 
plasma glucose (FPG) test in the past five years, (b) BMI > 25 kg/m2 and had not had an 
FPG test in the past five years, or (c) listed on the KPNC hypertension registry and had not 
completed an FPG test in the previous year. The risk criteria incorporated several elements 
of the ADA17 and USPSTF18 screening criteria that were current at the time, but focused on 
factors available in the electronic health record (EHR). Members were ineligible if they 
were less than 18 years old or were already known to have diabetes as indicated by being 
listed on the KPNC diabetes registry. Age, BMI, and FPG testing status were determined via 
the EHR. The KPNC diabetes and hypertension registries are created using EHR clinical 
data (e.g., labs, ICD9 codes, prescriptions, etc.) but are stand-alone databases maintained by 
the health plan. Members were included in the diabetes registry if they had two or more 
outpatient diabetes diagnoses or one or more inpatient or emergency department diagnoses, 
or they were on diabetes medications, except metformin alone, in the previous two years. 
Members were included in the hypertension registry if they had either two primary care 
diagnoses of hypertension or a combination of a primary care hypertension diagnosis and a 
hypertension medication, inpatient hypertension diagnosis, or stroke-related hospitalization 
in the previous two years. The diabetes and hypertension registries are updated on a 
quarterly basis. In order to take into account the most recent data available in the EHR, we 
further excluded members in the intervention group (8%) and control group (7%) if they had 
any of the following indications of diabetes or prediabetes at any time in the year leading up 
to the intervention: impaired fasting glucose diagnosis (ICD9 code 790.21), any diabetes 
diagnosis (ICD9 code 250), A1c ≥ 5.7%, or any diabetes medication (metformin, insulin, 
sulfonylureas, or thiazolidinediones).
Intervention
The screening program was developed by two employers and HealthWorks by Kaiser 
Permanente, a group that supports employers as they pursue workforce health efforts by 
providing consulting to develop health strategies and programs such as biometric screenings, 
health promotion classes, online wellness resources, and rewards programs.19 While the 
screening program was expected to identify a small number of diabetes cases, the focus of 
the program was on the larger number of people expected to be identified with prediabetes. 
At-risk members in the intervention group received letters stating that they were due for a 
lab test to determine if their blood glucose levels were in the prediabetes range. The letter 
included lab instructions for the member to present at any KPNC lab to complete an FPG 
test. Laboratories in the KPNC system are located in the same medical facilities where 
patients receive care and do not require an appointment. The members were not charged a 
copay for the visit by the health plan. The letter also reminded the members to fast for 12 
hours before completing the FPG test. The letter indicated that patients who know that their 
blood glucose level is in the prediabetes range may be motivated to take steps to prevent 
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developing diabetes. Members were also directed to a website that described KPNC 
resources to support healthy lifestyles, such as telephonic health coaching provided by the 
KPNC Wellness Coaching Center,20 online wellness resources, and in-person weight 
management classes. The letter was written in English or Spanish according the member’s 
primary language. It was printed on KPNC letterhead, and the printed signature was that of 
the member’s primary care physician. The employer was not listed on the letter, and 
individual-level responses to the intervention were not reported to the employer by KPNC. 
The same message was sent via secure email to members who utilized online access to their 
medical record through kp.org. The members who had not completed an FPG or A1c test 
one month after the letters were sent also received an automated reminder call; those who 
had not completed a screening within three months received a reminder letter. As physicians 
may have used the A1c test to screen for diabetes/prediabetes in usual care, we used both 
FPG and A1c tests to establish who had completed a screening. While FPG and A1c tests 
have imperfect concordance for the diagnosis of diabetes,21 the ADA guidelines allow for 
the use of either test and provide a range of values that indicate diabetes and prediabetes for 
both tests.3
In January 2013, the members who had tested in the prediabetes range (an FPG value 
between 100 and 125 mg/dL or an A1c value between 5.7 and 6.4%) were sent a letter from 
KPNC that informed them of their prediabetes status and instructed them to contact their 
primary care physician with questions. The letter also provided recommendations to be 
physically active, eat healthy foods, quit tobacco and offered resources to support them in 
their efforts (e.g., telephonic health coaching).20
Statistical analyses
We compared the baseline characteristics of the intervention and control groups on age, 
gender, race/ethnicity, and utilization (number of primary care visits in previous year, and 
whether the patient had completed an FPG or A1c within five years). Using Census 2010 
data, we also compared the two groups on geocoded education (the percentage of 
individuals aged 25 and older with a bachelor’s degree in the Census block a patient lives in) 
and geocoded median household income (the median household income of the Census block 
a patient lives in). Lastly, we compared the groups on BMI, tobacco use, hypertension 
diagnosis (ICD9 code 401-405), systolic blood pressure ≥ 140 mmHg, hyperlipidemia 
diagnosis (ICD9 code 272), and having an abnormal cholesterol value (LDL ≥ 130, 
triglycerides ≥ 200, or HDL ≤ 60) in the previous year.
The primary outcome measure was the proportion of eligible persons in the intervention and 
control groups who were screened for diabetes/prediabetes in the six months after the 
intervention (September 2012 – March 2013). For both groups, the laboratory test had to be 
ordered by a physician or other care provider; the employees could not self-refer. In the 
intervention group, we also compared the three at-risk groups on the proportion who 
completed a screening. As members could qualify for more than one at-risk group, members 
were assigned to a group by the following hierarchy: listed on the hypertension registry and 
had not completed an FPG test in the previous year, BMI > 25 kg/m2 and had not had an 
FPG test in the past five years, aged 45 or older and had not had an FPG test in the past five 
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years. In addition, we report the proportion that had blood glucose values in the prediabetes 
range (defined as above) or diabetes range (defined as an FPG > 125mg/dl or A1c > 6.4%) 
in the six-month observation period. While not a primary outcome of this intervention, we 
also examined the rate of follow-up among the members in the intervention group who had a 
positive screen for prediabetes or diabetes and who had continuous health plan enrollment 
for the following year. We examined the EHR data for a record of a repeated blood glucose 
test (FPG or A1c), a diabetes or impaired fasting glucose diagnosis (ICD9 code 250 or 
790.21, respectively), a related clinical progress note (e.g. a clinical note referring to 
prediabetes, diabetes, health behavior, and self-management), or a referral to or participation 
in a related KPNC service (e.g. in-person lifestyle class, telephonic health coaching, or 
nutritional counseling) in the year following the elevated lab.
Two sample t tests and Pearson chi-square tests of independence were used to compare the 
intervention and control groups on baseline characteristics and study outcomes. In order to 
compare the primary outcome in the two groups while adjusting for potential differences in 
baseline characteristics, we performed a logistic regression model with the following 
independent variables: indicator for the intervention/control group, age, gender, race/
ethnicity, FPG/A1c within 5 years, number of primary care visits in previous year, geocoded 
education, geocoded income, BMI, tobacco use, hypertension diagnosis, high systolic blood 
pressure (≥ 140 mmHg), hyperlipidemia diagnosis, and abnormal cholesterol levels (LDL ≥ 
130, triglycerides ≥ 200, or HDL ≤ 60). To examine the baseline characteristics associated 
with responding to this outreach method, we implemented a multivariate relative risk model 
for predicting screening adjusting for the baseline characteristics described above among the 
patients in the intervention group with non-missing covariates. Since the outcome was not 
rare, a modified Poisson regression was used to estimate risk ratios, rather than using a 
logistic regression to estimate the odds ratios.22-24 We also evaluated and ranked the relative 
importance of each individual patient characteristic (e.g. age or race) in predicting the 
diabetes or prediabetes risk of patients in the intervention arm. Since we did not know the 
diabetes or prediabetes status of everyone in the intervention arm because not all members 
in the intervention arm were screened, we implemented inverse probability of treatment and 
censoring weighted estimation of variable importance.25-28 This approach aims to evaluate 
the independent impact of each individual baseline characteristic by controlling for, not 
only, potential confounding from all other remaining baseline characteristics, but also, 
potential selection bias29 due to differential screening rates. All tests were two-sided with an 
alpha level of 0.05 to determine statistical significance. SAS software version 9.3 (SAS 
Institute Inc., Cary, NC) was used for all data management and analysis.
Results
A total of 684 members at the intervention sites and 1,050 members at the control sites met 
the inclusion criteria for being at-risk and were included in the analysis. The intervention 
and control groups had similar mean age (51 vs. 53 years, P = .06), gender distribution (56% 
female vs. 53%, P = .15), prevalence of overweight/obesity (75% vs. 74%, P = .18), and 
prevalence of hypertension (35% vs. 35%, P = .76, Table 1). The intervention and control 
groups had significant differences in race/ethnicity (53% vs. 73% White, P < .001), 
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geocoded education (see Table 1 for distribution, P < .001), and geocoded Census block-
level annual household income (47% with $80,000 or more vs. 35%, P < .001).
In the six months following the outreach, the proportion of patients who came in for 
screening was significantly higher in the intervention group than in the control group. More 
than a third (36%) of the members in the intervention group were screened with an FPG or 
A1c test, compared to 13% in the control group (P < .001, adjusted for patient 
characteristics, Figure 1). We also examined the screening rates in the intervention group 
stratified by the three risk-based criteria used to identify members for this study. The group 
that had hypertension and no FPG within one year came in for screening at a higher rate 
(64%) than the groups who had not had an FPG within five years and who were aged ≥ 45 
(21%) or who had BMI > 25 (23%, P < .001, Figure 1).
Among the screened, approximately one third of both the intervention and control groups 
had a FPG or A1c value in the prediabetes range (33% vs. 34%, P = .68, adjusted for patient 
characteristics, Figure 2). A small number of members in the intervention group (n = 6) and 
control group (n = 6) had these values in the diabetes range (2% vs. 4%, P = .33, adjusted 
for patient characteristics). A comparison of the at-risk groups revealed that they had similar 
rates of positive screening for diabetes and prediabetes: 28% of the age ≥ 45 group, 34% of 
the BMI > 25 group, and 39% of the hypertension group had a lab in the diabetes or 
prediabetes range (P = .43, Figure 2).
After multivariate risk adjustment, members in the intervention group age 60 or older and 
Asians were more likely to complete a screening after receiving the screening invitation 
(Table 2). Members with at least one FPG or A1c test in the previous five years and those 
with at least one primary care visits in the previous year (vs. those with no visits) were more 
likely to complete a screening. Hypertension status and having a high BMI were not 
significant predictors of being screened. After multivariate adjustment and weighting for the 
inverse probability of being screened, predictors of an elevated FPG or A1c level included 
high versus normal weight, hypertension, hyperlipidemia, current tobacco use, FPG or A1c 
measured during the previous five years, and two or more primary care visits in the previous 
year.
Although the screening intervention was not designed to provide follow-up care directly, we 
also examined the rates of follow-up treatment and diagnosis provided to the members in the 
intervention group with a positive screen (n = 86). Two-thirds (66%) of these employees had 
evidence of a clinical response within 12 months: 20% received a diagnosis of diabetes or 
impaired fasting glucose, 34% had their FPG or A1c levels retested, and 50% had a clinical 
note in their EHR record that related to diabetes or prediabetes (data not shown).
Conclusions
This employer-based screening program conducted as a partnership with a health care 
provider roughly tripled the screening rate observed in a similar usual-care population. This 
low-intensity intervention targeted patients based on demographic, clinical, and utilization 
data that were available through the EHR, and contacted patients in the intervention group 
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by sending letters, secure emails, and voice messages using existing health plan personnel 
resources. These practical approaches to screening for diabetes/prediabetes could easily be 
replicated by other health care systems seeking to increase screening, particularly among 
employer-based populations.
Given employers’ current interest in diabetes prevention, workforce prompts for diabetes 
screening in the health care setting in the manner described here may be an effective avenue 
to increase screening rates. Employer-based prompts for screening may reach people who 
are not currently being screened in the primary care setting, as many people, especially 
relatively healthy people, do not visit a primary care provider every year. Collaboration with 
a health plan allowed the employers in this study to increase screening within a health care 
setting, which the ADA recommends so that patients are more likely to receive the 
appropriate follow-up testing and care.3 In our examination of follow-up treatment and 
diagnosis in the year following a positive screen, two-thirds of patients in the intervention 
group received a clinical response that was documented in the EHR. The rate of follow-up 
for this cohort was in line with a previous study of prediabetes recognition and treatment in 
the entire KPNC population, although that study was limited to a six month observation 
period.30 While there are various KPNC resources available to patients to support lifestyle 
modification (e.g. nutritional services, telephonic health coaching, and in-person classes), at 
the time of this intervention KPNC did not have a standard protocol for referring patients 
with prediabetes for services.
This intervention attempted to lower barriers to screening. Members were not required to 
make an appointment or obtain pre-approval to complete the screening. Members were not 
charged a copay for the visit. KPNC laboratories are collocated with other medical offices; 
therefore patients could have elected to combine the diabetes/prediabetes screening with an 
unrelated visit to the medical center. Nevertheless, getting to the laboratory and fasting prior 
to the FPG test may have been significant barriers to completing the screening.
Despite the intervention’s success in improving screening rates, two-thirds of the members 
at-risk for prediabetes in the intervention group did not complete a glucose screening within 
six months. Efforts to reduce the number of undetected diabetes and prediabetes cases will 
require a multipronged approach that includes increasing screening in the primary care 
setting and providing more outreach programs to reach the people not screened through 
primary care. More research is needed on outreach programs that will effectively and 
efficiently achieve greater screening rates. This study found that a low-intensity intervention 
that involved standard health plan communication mechanisms was effective in improving 
screening rates especially among members who were older and more engaged with the 
health care system (i.e. those with one or more primary care visit in the previous year and 
those who had had an FPG or A1c within five years). A more intensive outreach program 
may be needed to get younger members and members less engaged with the health care 
system to complete a blood glucose test.
Approximately one-third of those screened in both the intervention and control groups had a 
positive test for prediabetes. A similar proportion of positive tests for prediabetes was 
reported in a predictive model of the 2014 ADA screening guidelines applied to the 2010 
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U.S. population. That study found that of the 86.3 million who met the 2014 ADA screening 
criteria, an estimated 39% (33.9 million) would have prediabetes. 31 As more outreach 
programs are developed that target specific groups for screening, one measure of efficiency 
may be to increase the proportion of positive screens. The results of this study indicate that 
targeting patients with risk factors such as being obese, having comorbidities such as 
hypertension or hyperlipidemia, and having certain health behaviors, such as tobacco use 
and infrequent primary care visits, would increase the proportion with positive screens.
There are several limitations that should be noted. We were not able to conduct a cost-
benefit analysis of this intervention. In addition, we were not able to incorporate any secular 
trends in screening rates. We categorized screening results based on one lab value, but it is 
worth noting that the ADA recommends that the test be repeated before making a 
diagnosis.3 Another potential limitation of this intervention is that the selection criteria 
identify so many patients that the outreach is not scalable to the entire population. Almost a 
quarter of the employee population qualified, and extending this outreach to the entire 
KPNC population would require sending more than 400,000 letters along with the other 
communications. The infrastructure to provide the outreach and complete the screening 
would need to be built up to accommodate a full implementation of this intervention.
Targeted risk-based screening for prediabetes is a critical first step to preventing type 2 
diabetes. Employer-health plan partnerships can be an effective way to increase screening 
rates in employees with risk factors for type 2 diabetes. Future research should focus on 
disseminating and implementing diabetes/prediabetes screening programs on a wider basis, 
and continue to explore the best methods to encourage screening among patients who do not 
respond to low-intensity outreach.
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Figure 1. 
Proportion screened within six months for the intervention and control groups and for the 
intervention group stratified by the at-risk categories
* Adjusting for age, sex, race/ethnicity, FPG/A1c within 5 years, number of primary care 
visits in previous year, geocoded education, geocoded income, BMI, tobacco use, 
hypertension diagnosis, high systolic blood pressure, hyperlipidemia diagnosis, and 
abnormal cholesterol levels, the tests for the differences in proportions between the 
intervention and control groups were P < .001 for screened with FPG or A1c; P < .001 
screened with FPG; P = .21 screened with A1c only.
† χ2 test for the difference in proportions between the at-risk groups for members in the 
intervention group: screened with FPG or A1c, P < .001; screened with FPG only, P < .001; 
screened with A1c only, P = .04.
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Figure 2. 
Proportion with a blood glucose test in the diabetes or prediabetes range among those 
screened within six months for the intervention and control groups and for the intervention 
group stratified by the at-risk categories
* Adjusting for age, sex, race/ethnicity, FPG/A1c within 5 years, number of primary care 
visits in previous year, geocoded education, geocoded income, BMI, hypertension diagnosis, 
high systolic blood pressure, hyperlipidemia diagnosis, and abnormal cholesterol levels, the 
tests for the differences in proportions between the intervention and control groups were P 
= .68 for screened in prediabetes or diabetes range; P = .84 for screened in the prediabetes 
range; P = .33 for screened in the diabetes range.
† χ2 test for the difference in proportions between the at-risk groups for the intervention 
group: prediabetes, P = .49; diabetes, P = .62; diabetes or prediabetes, P = .43.
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Table 1
Baseline characteristics of the intervention and control groups
Intervention Control P value*
n 684 1050
Age, mean (SD) 51 (17) 53 (16) .06
Female, n (%) 384 (56) 552 (53) .15
Race/ethnicity, n (%) <.001
 Asian 60 (9) 52 (5)
 African-American 71 (10) 52 (5)
 Hispanic 100 (15) 80 (8)
 White 363 (53) 763 (73)
 Other/unknown 90 (13) 103 (10)
FPG or A1c within five years, n (%) 216 (32) 304 (29) .24
Primary care visits in prior year, n (%) .24
 0 247 (36) 330 (31)
 1 170 (25) 286 (27)
 2-3 162 (24) 266 (25)
 4 or more 105 (15) 168 (16)
Geocoded education, n (%) <.001
 Less than 15% with bachelor’s degree or more 122 (18) 126 (12)
 15-29% with bachelor’s degree or more 233 (34) 393 (37)
 30-44% with bachelor’s degree or more 154 (23) 305 (29)
 45% or more with bachelor’s degree or more 172 (25) 222 (21)
Geocoded annual household income, n (%) <.001
 Less than $50,000 125 (18) 246 (23)
 $50,000 to less than $80,000 236 (35) 431 (41)
 $80,000 to less than $120,000 245 (36) 319 (30)
 $120,000 or more 75 (11) 50 (5)
BMI (kg/m2)
 Mean (SD) 29.5 (6.3) 29.4 (6.5) .64
 Normal (BMI < 25 kg/m2), n (%) 126 (18) 220 (21) .18
 Overweight (BMI 25- < 30 kg/m2), n (%) 264 (39) 412 (39)
 Obese (BMI ≥ 30 kg/m2), n (%) 246 (36) 367 (35)
 Missing, n (%) 48 (7) 51 (5)
Current tobacco user, n (%) 51 (7) 73 (7) .69
Hypertension diagnosis, n (%) 242 (35) 364 (35) .76
Systolic blood pressure ≥ 140 mmHg, n (%) 108 (16) 167 (16) .95
Hyperlipidemia diagnosis, n (%) 119 (17) 187 (18) .83
Abnormal cholesterol level†, n (%) 154 (23) 251 (24) .50
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*
Determined by a χ2 test for the difference in proportions or a t test for the difference in means.
†Abnormal cholesterol level was defined as LDL ≥ 130, triglycerides ≥ 200, or HDL ≤ 60.
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Table 2
Multivariate relative risk models for completing a screening in the intervention group given the baseline 
characteristics of patients and estimates of the relative importance of each baseline characteristic in having a 
test in the diabetes or prediabetes range
Completing a screening Having a test in the diabetes
or prediabetes range*
Patient Characteristics Relative risk P value Relative risk P value
Age
 40-59 vs. 18-39 1.2 .22 1.1 .75
 60+ vs. 18-39 1.6 .01 1.0 .96
Female 1.1 .30 1.3 .20
Race/ethnicity
 African-American vs. Asian 0.5 .01 0.7 .36
 Hispanic vs. Asian 0.7 .02 1.0 .89
 White vs. Asian 0.7 .01 0.7 .13
 Other/unknown vs. Asian 0.5 .01 0.5 .17
FPG/A1c within five years 1.4 .01 0.7 .03
Primary care visits in prior year
 1 vs. 0 1.6 .004 0.7 .11
 2-3 vs. 0 1.6 .003 0.6 .054
 4 or more vs. 0 1.6 .01 0.5 .02
Geocoded education
 < 15% vs. ≥ 45% with bachelor’s degree or
more
0.9 .78 0.8 .48
 15 - 29% vs. ≥ 45% with bachelor’s degree
or more
1.1 .47 0.9 .74
 30 - 44% vs. ≥ 45% with bachelor’s degree
or more
0.9 .67 1.3 .18
Geocoded annual household income
 < $50,000 vs. ≥ $120,000 0.7 .07 0.8 .43
 $50 - < $80,000 vs. ≥ $120,000 0.8 .15 0.8 .29
 $80 - < 120,000 vs. ≥ $120,000 0.8 .13 0.9 .58
BMI
 Overweight (BMI 25- < 30 kg/m2) vs. BMI
< 25 kg/m2 1.1 .40 1.0 .99
 Obese (BMI ≥ 30 kg/m2) vs. BMI < 25
kg/m2 1.1 .61 2.0 .006
Current tobacco user 0.7 .10 3.1 <.001
Hypertension diagnosis 1.3 .11 1.8 .002
Systolic blood pressure ≥ 140 mmHg 0.9 .63 0.9 .67
Hyperlipidemia diagnosis 1.0 .85 1.8 <.001
Abnormal cholesterol level† 1.0 .96 0.9 .36
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*Weighted by the inverse probability of completing a blood glucose test.
†Abnormal cholesterol level was defined as LDL ≥ 130, triglycerides ≥ 200, or HDL ≤ 60.
J Occup Environ Med. Author manuscript; available in PMC 2016 November 01.
